The finding arrives at a moment when the antifungal armamentarium is thinning dangerously. Unlike the dozens of antibiotic classes available against bacteria, antifungal drugs come from only a handful of structural families: the polyenes, which bind ergosterol and punch holes in fungal membranes; the azoles, which block ergosterol biosynthesis; the echinocandins, which inhibit the synthesis of β-glucan, the wall’s main load-bearing polysaccharide; and the older nucleoside analogue flucytosine. Each carries liabilities. Amphotericin B, the workhorse polyene, is notoriously nephrotoxic; azole resistance is now entrenched in clinical populations; and echinocandin resistance is climbing in both Candida auris and Candida glabrata through mutations in the drug’s target enzyme. The deeper problem is evolutionary. Fungi are eukaryotes, our distant cousins on the tree of life, and many of their core cellular processes — from DNA replication to protein synthesis — resemble our own so closely that they make poor drug targets. That bottleneck has pushed researchers toward the one structure human cells conspicuously lack: the fungal cell wall, a rigid exoskeleton of cross-linked polysaccharides and glycoproteins that the cell must continuously remodel in order to grow, divide and withstand osmotic pressure.

Within that wall, chitin occupies a special position. Chemically, it is a linear polymer of N-acetylglucosamine units joined by β-1,4 glycosidic bonds — the same linkage architecture that stitches cellulose together in plants — and it forms a tough inner scaffold beneath the outer layers of β-glucan and mannoproteins. Although chitin accounts for only a small fraction of the wall’s dry mass in Candida, its structural role is outsized: it concentrates at the bud necks where daughter cells emerge and at the septa that divide one cell from another, acting as a load-bearing ring during the most mechanically stressful moments of the yeast life cycle. Crucially for medicine, fungi treat chitin as a rescue material. When echinocandin drugs suppress β-glucan synthesis, Candida cells often respond by thickening their chitin layer, and elevated chitin content has been linked to echinocandin treatment failure. An agent that attacks chitin directly would therefore strike not only a wall component in its own right, but also the very contingency plan that fungi deploy when other drugs arrive — and because humans neither synthesize chitin nor build any structural tissue from it, the polymer offers a selectivity gradient that conventional metabolic targets rarely achieve.

Chitinases — the glycoside hydrolase enzymes that cleave those β-1,4 bonds — are everywhere in nature, and the ocean is their great engine room. Marine ecosystems recycle enormous quantities of chitin every year from crustacean molts, krill, plankton and other arthropod debris, and marine bacteria have evolved elaborate chitinolytic systems to exploit this bonanza as their primary carbon and nitrogen source. Enzymes forged in seawater often carry useful biochemical gifts: tolerance to salt, robustness across pH ranges and a stability profile that terrestrial counterparts do not always match. The Indian team tapped this reservoir, expressing the BtChi enzyme in the laboratory and purifying it as a 71-kilodalton protein with a total activity of 438.6 units. When the purified preparation was titrated against a panel of Candida species, minimum inhibitory concentrations ranged from 7.8 to 250 micrograms per milliliter depending on the species — a spectrum the authors characterize as broad yet species-specific, consistent with the idea that different Candida species expose or shield their wall chitin to different degrees.

The standout result concerned Candida auris. Across the tested isolates, the enzyme delivered an MIC50 of 3.9 micrograms per milliliter and an MIC90 of 7.8 micrograms per milliliter, meaning that half of the strains were inhibited at the lower concentration and ninety percent at the higher one. Those numbers matter because of what C. auris represents. Since its simultaneous global emergence on three continents in the mid-2010s, the yeast has caused outbreaks in intensive care units across dozens of countries, persists on hospital surfaces and human skin for weeks, shrugs off many common disinfectants, and routinely defies fluconazole while amphotericin B and echinocandin failures accumulate. Many clinical isolates qualify as multidrug-resistant, and a worrying minority have proven pan-resistant, leaving clinicians with almost no options. Against this backdrop, any molecule that inhibits the organism at single-digit microgram concentrations commands attention — and one that does so by physically digesting a structural polymer, rather than poisoning a metabolic enzyme, may be harder for the fungus to circumvent through the familiar route of target-site mutation.

Inhibiting growth is one thing; killing cells outright is another. The researchers therefore ran time-kill assays, tracking viable colony-forming units over hours of enzyme exposure. For most of the Candida species tested, BtChi achieved reductions of at least 3 log10 CFU per milliliter — a thousand-fold drop, the conventional benchmark for fungicidal activity — within a window of 12 to 20 hours. Two species broke the pattern: Candida parapsilosis, with a maximum reduction of 1.67 log10 CFU per milliliter, and C. auris, with 0.4 log10. The authors describe the enzyme’s profile as fungicidal-like and species-dependent, and the heterogeneity is informative rather than merely disappointing. Cell wall architecture varies substantially across the Candida genus: the ratio of β-glucan to chitin, the density of the outer mannoprotein coat, and the efficiency of wall-repair and stress-response pathways all differ from species to species, and any of these factors could modulate how readily a 71-kilodalton protein reaches and dismantles the chitin layer beneath. For C. auris, the potent inhibition reflected in its low MIC values suggests that the enzyme suppresses the fungus effectively even where outright killing lags behind.

Two independent lines of evidence then tied the antifungal effect to chitin digestion. Microscopic analysis — carried out using confocal imaging facilities at the Manipal School of Life Sciences and scanning electron microscopy at the Central Research Facility of NITK Surathkal — revealed clear cell wall damage in enzyme-treated cells, structural disruption of precisely the layer the enzyme is built to attack. Complementing the imaging, high-performance liquid chromatography performed at the School of Civil and Chemical Engineering detected the release of monomeric, dimeric and trimeric chitooligosaccharides from the treated cultures. Those small soluble sugars are the expected products of chitinase action: the enzyme processively hydrolyzes the β-1,4 backbone of chitin, clipping the insoluble polymer into short oligosaccharides and, ultimately, N-acetylglucosamine monomers. Observing the wall physically compromised while its digestion products accumulate in solution gives the mechanistic argument a satisfying closed loop. The enzyme binds its substrate within the wall, cuts, and the wall’s integrity fails, leaving the cell to buckle under its own internal turgor pressure — a mode of death that looks less like metabolic poisoning and more like structural demolition.

The therapeutic logic extends beyond monotherapy. Because echinocandin stress drives fungi to reinforce their walls with extra chitin, a chitinase could in principle subvert that rescue response, sensitizing cells to existing drugs or dismantling the very mechanism behind echinocandin failure. The chitooligosaccharides that BtChi releases are not inert debris, either: short chitin oligomers are recognized by innate immune systems and act as biological signals in contexts ranging from plant defense priming to mammalian immunology, adding a possible second layer of activity. Enzyme-based antimicrobials also carry an appealing property at a time when resistance dominates the headlines — resistance through target mutation is difficult to evolve against a physical polymer that the cell cannot simply redesign without paying a steep fitness cost. The caveats, however, are real. Delivering a 71-kilodalton protein systemically poses challenges of proteolytic degradation, immunogenicity, manufacturing cost and tissue penetration, and no enzyme antifungal has yet navigated the full path of clinical development. Nearer-term applications may therefore lie in topical formulations, catheter-lock solutions, wound dressings or agricultural protection, where protein drugs face fewer delivery barriers and where biofilms of Candida on medical devices remain a persistent problem.

For now, the study stands as a proof of concept that a single marine enzyme can, on its own, cripple the walls of some of the most clinically feared Candida species. The authors, whose team included co-first authors Rachana Arvind and Smruti Bhat, frame the work around three key points: BtChi exhibits species-specific antifungal activity; it produces species-dependent fungicidal effects in killing kinetics against C. albicans and non-albicans species; and it targets chitin in the Candida cell wall while releasing chitooligosaccharides. Translating that chemistry into medicine will require stability engineering, delivery vehicles and rigorous safety profiling, steps that typically span years and substantial investment. But the direction of travel is unmistakable. The World Health Organization’s first fungal priority pathogens list placed C. auris in its critical group, and the pipeline of genuinely new antifungal classes remains conspicuously thin even as invasive fungal infections claim well over a million lives each year. An enzyme that ocean bacteria use to recycle crab shells and krill may not reach the pharmacy soon, yet it demonstrates something the field badly needs: that the fungal wall’s most stubborn material can be made to fail, and that the next generation of antifungals may be built not to poison cells but to take them apart.

The team focused on polyenes, a powerful class of membrane-active compounds widely exemplified by amphotericin. While amphotericin can be effective, its therapeutic window is narrow because fungal cells share key structural features with human cells, increasing the risk of serious side effects.

Using genome mining, the researchers searched bacterial genomes for biosynthetic pathways predicted to produce previously undiscovered polyenes. Instead of relying on traditional trial-and-error discovery, they combined computational prediction with chemical characterization to uncover novel molecular frameworks.

Once candidate molecules were identified, the group used nuclear magnetic resonance (NMR) spectroscopy to resolve the structures of the new polyenes. Each compound displayed a distinct architecture, indicating that microbial biosynthesis can diversify polyene chemistry beyond what is represented in existing antifungal libraries.

To understand and exploit this diversity, the researchers characterized the enzymes responsible for building the molecules and assembled a set of polyene derivatives for functional testing. Central to the approach was enzymatic remodeling, including glycosylation and amidation steps that reshape bioactivity while preserving antifungal potency.

In mouse experiments, several derivatives showed improved antifungal activity accompanied by reduced toxicity and better solubility relative to parent drugs. The most notable candidate, Nys34, reduced fungal burden in a model of invasive aspergillosis caused by Aspergillus fumigatus without substantial signs of toxicity.

The study also highlights a crucial pharmacological point: Nys34 appears to kill fungal cells via a mode of action different from amphotericin. That divergence may help preserve efficacy against emerging pathogens that have evolved resistance to amphotericin.

Beyond efficacy, the platform offers a manufacturing advantage. By using enzymes rather than multi-step chemical synthesis, the researchers propose a cleaner and potentially scalable route to optimized antifungal compounds, with relevance for broader global access.

<

h4>Subject of Research: Enzymatic redesign of polyene antifungal agents for safer, more effective therapies
Article Title: Enzymatic glycosylation and amidation reshapes polyene bioactivity
News Publication Date: 29-Jul-2026
Web References: https://www.nature.com/articles/s41586-026-10834-8
References: 10.1038/s41586-026-10834-8
Image Credits: Professor Jason Micklefield

Keywords

Polyene antifungals; genome mining; NMR structure determination; glycosylation; amidation; enzymatic drug design; invasive aspergillosis; antimicrobial resistance

Fungal infections pose a significant threat to both human health and agriculture, leading to substantial morbidity and mortality worldwide. The increasing prevalence of drug-resistant fungal species highlights the urgent need for new treatments. Traditional antifungal agents often come with limitations, including toxicity, side effects, and the rapid emergence of resistance. This has propelled scientists to explore new chemical frameworks, with isoquinoline derivatives emerging as viable candidates in the search for more effective antifungal therapies.

The research team’s primary objective was to synthesize a series of isoquinoline derivatives that incorporate an oxime functional group. Previous studies have indicated that oxime-containing compounds can exhibit varied biological activities, making them attractive scaffolds for the development of antifungal agents. By leveraging the unique structural characteristics of isoquinoline and the biological potential of oxime moieties, the researchers set out to create compounds with enhanced antifungal properties.

The synthesis of these novel isoquinoline derivatives involved a multi-step process that required careful optimization of reaction conditions. The team employed several synthetic methodologies, including cyclization and functional group modifications, to achieve the desired compounds. Each step of the synthesis was meticulously monitored, and the products were characterized using advanced analytical techniques such as nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry. This rigorous approach ensured high purity and structural integrity of the final antifungal agents.

As the research team progressed, they conducted a series of antifungal assays to evaluate the bioactivity of their synthesized isoquinoline derivatives. These assays were designed to assess the compounds’ effectiveness against a broad spectrum of fungal pathogens, including clinically relevant strains known for their resistance to conventional antifungals. The results were promising, with several derivatives displaying potent antifungal activity, indicating their potential as therapeutic agents.

One of the intriguing aspects of this study is the detailed mechanistic investigation undertaken by the researchers. They sought to understand how these novel compounds interact with fungal cells at the molecular level. By employing techniques such as molecular docking studies and microscopy, the team was able to elucidate the binding interactions between the isoquinoline derivatives and key cellular targets within the fungi. This level of detail is crucial for refining the design of compounds and improving their effectiveness.

Furthermore, the researchers identified potential pathways through which these antifungal agents may disrupt fungal cell function. For instance, it was discovered that certain isoquinoline derivatives could interfere with critical biochemical processes, such as ergosterol biosynthesis, a vital component of the fungal cell membrane. By targeting this pathway, the compounds were able to induce cell membrane damage, ultimately leading to cell death in susceptible fungal strains.

The implications of these findings extend beyond academic interest. Given the rising incidence of fungal infections and the associated healthcare burdens, the development of more effective antifungal agents is of paramount importance. The research by Jin and colleagues not only contributes to the scientific literature but also holds promise for future therapeutic applications, providing a possible avenue for addressing the growing challenge of fungal resistance.

Although the study underscores the potential of these isoquinoline derivatives as antifungal agents, it also highlights the ongoing challenges within drug development. Depending on the compound’s molecular structure, variations in efficacy and toxicity profiles can arise. Therefore, further studies will be necessary to comprehensively evaluate the safety and efficacy of these new agents in clinical settings. Such evaluations will be critical in determining the viability of these compounds as candidates for further development.

In conclusion, the work by Jin, Chen, Long, and their team represents a significant stride in the quest for new antifungal agents by presenting an innovative class of compounds. Their careful consideration of the design, synthesis, and mechanism of action provides a solid foundation for future research endeavors. As the battle against fungal infections continues, the insights gleaned from this study may accelerate the discovery of effective treatments, offering hope to countless individuals affected by these invasive pathogens.

This exploration into isoquinoline derivatives containing oxime moieties embodies the spirit of scientific discovery, showcasing how targeted research can yield promising new avenues for combating global health threats. The ongoing research and potential clinical applications stemming from this study will undoubtedly attract the attention of pharmaceutical developers and researchers alike, driving forward the urgent need for effective antifungal strategies in the face of emerging resistance.

Subject of Research: Antifungal agents using isoquinoline derivatives.

Article Title: Design, synthesis, and mechanism study of novel isoquinoline derivatives containing an oxime moiety as antifungal agents.

Article References:

Jin, Y., Chen, F., Long, Y. et al. Design, synthesis, and mechanism study of novel isoquinoline derivatives containing an oxime moiety as antifungal agents.
Mol Divers (2025). https://doi.org/10.1007/s11030-025-11317-0

Image Credits: AI Generated

DOI: 10.1007/s11030-025-11317-0

Keywords: Isoquinoline derivatives, antifungal agents, oxime moiety, drug resistance, synthesis, mechanism of action.